Previous 10 | Next 10 |
2024-02-02 02:15:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical ...
2024-01-26 15:33:29 ET Summary Alkermes plc expects to have additional results from the phase 1b proof-of-concept study, using ALKS-2680 for the treatment of patients with narcolepsy, in the 1st half of 2024. An update on the advancement of a phase 2 study, using ALKS-2680 for the...
2024-01-26 14:15:33 ET Summary Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility. Despite a turbulent year, Alkermes' stock price remains relatively stable, but ...
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and u...
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) PR Newswire — Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight an...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
Originally published in Alkermes September 2023 Corporate Responsibility Report NORTHAMPTON, MA / ACCESSWIRE / December 27, 2023 / Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and comm...
NORTHAMPTON, MA / ACCESSWIRE / December 20, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Board of Directors Our Board is currently comprised of eleven members, each of whom has a term expiring at the Company's 2024 annual general meeting o...
NORTHAMPTON, MA / ACCESSWIRE / December 18, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Ethics and Compliance Integrity is a core Alkermes value and the foundation of the way we do business. Alkermes is dedicated to upholding legal, regul...
NORTHAMPTON, MA / ACCESSWIRE / December 14, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Employee engagement remained a top priority for the Company throughout 2022. As many of our office-based employees have adapted to a hybrid work model, w...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc Company Name:
ALKS Stock Symbol:
NASDAQ Market:
2024-05-29 01:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PR Newswire – Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations ...